# Elevance Health, Inc. – Consensus ‘buy’ rating and 25.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/elevance-health-inc.consensus-buy-rating-and-25.9-upside-potential/4121131015
- Published: 2023-10-26T13:38:18+01:00
- Author: Charlotte Edwards

**Elevance Health, Inc.** which can be found using ticker (ELV) now have 17 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The target
price High/Low ranges between 629 and 500 and has a mean target at $570.00. Given
that the stocks previous close was at $452.59 this indicates there is a potential
upside of 25.9%. The day 50 moving average is $451.19 and the 200 moving average
now moves to $462.10. The market cap for the company is 105.75B. The stock price
for the company is currently 450.07 USD

 The potential market cap would be $133,180,942,514 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 17.51, revenue per share of 711.73
and a 5.25% return on assets.

Elevance Health, Inc. is a health company. It operates as a health insurer in the
United States. The Company operates through four segments: Health Benefit, CarelonRx,
Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive
suite of health plans and services to individual, employer group risk-based, employer
group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits(
FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx
markets and offers pharmacy services to affiliated health plan customers, as well
as to external customers outside of the health plans. Carelon Services offers a 
broad array of healthcare-related services and capabilities to internal and external
customers including integrated care delivery, behavioral health, palliative care,
utilization management, payment integrity services and subrogation services, as 
well as health and wellness programs.

Share on: